IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

IceCure (NASDAQ: ICCM) announced that Thomas Hospital of Fairhope, part of Infirmary Health, purchased and installed the ProSense® cryoablation system, becoming the first hospital in Alabama to offer breast cancer cryoablation.

Rhea-AI Summary

IceCure (NASDAQ: ICCM) announced that Thomas Hospital of Fairhope, part of Infirmary Health, purchased and installed the ProSense® cryoablation system, becoming the first hospital in Alabama to offer breast cancer cryoablation. Procedures are scheduled to begin in the coming weeks, funded by the Thomas Hospital Foundation. The move follows the October 2025 FDA clearance for local treatment of low-risk breast cancer and growing clinical interest.

Positive

• October 2025 FDA clearance for ProSense® in low-risk breast cancer
• Thomas Hospital is the first facility in Alabama to offer breast cryoablation
• Purchase funded by the Thomas Hospital Foundation, enabling community access
• Procedures to begin in the coming weeks at a large Infirmary Health hospital

Negative

• None.

Argus Feb 19 session

-0.12% close to close Open Argus

Details

News Market Reaction – ICCM

On Feb 19, the day this news came out, ICCM closed 0.12% below the previous close.

Data tracked by StockTitan Argus for the Feb 19 session.

Key Figures

ProSense® sales 2025: $3.4 million Cash & equivalents: $8.9 million CPT III reimbursement: $4,049 +5 more

ProSense® sales 2025

$3.4 million

Preliminary unaudited full-year 2025 sales

Cash & equivalents

$8.9 million

As of December 31, 2025 (preliminary)

CPT III reimbursement

$4,049

ProSense® procedure reimbursement effective January 2026

ATM capacity

$13,960,500

Equity distribution agreement through Maxim Group LLC

Addressable patients

200,000 women annually

U.S. breast cryoablation population cited in filings

2025 distributions

$2.83 per share

AIV 2025 distributions, 100.00% capital gain

Capital gain portion

100.00%

AIV 2025 distributions classified as total capital gain

Unrecaptured Sec. 1250 gain

33.7355%

Portion of AIV 2025 distributions

Historical Context

5 past events · Latest: Feb 11

5 events

1. Feb 11

   New U.S. site

   24h Move

   -1.8%

   First Missouri clinic offers ProSense® breast cancer cryoablation, expanding access.

2. Feb 09

   Management change

   24h Move

   +1.8%

   Planned CFO departure with transition period and active search for successor.

3. Jan 28

   Guideline inclusion

   24h Move

   +0.0%

   ASBrS draft guidelines include cryoablation for select low-risk breast cancer.

4. Jan 15

   Dividend tax data

   24h Move

   -0.5%

   AIV details 2025 dividend tax allocation and capital gain composition.

5. Jan 12

   Record sales update

   24h Move

   -5.5%

   Preliminary 2025 ProSense® record sales and cash position disclosure.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cryoablation, Food and Drug Administration

2 terms

cryoablation medical

"a developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

Food and Drug Administration regulatory

"following the October 2025 Food and Drug Administration ("FDA") clearance"

A government agency that reviews and regulates medicines, medical devices, food safety, and related products to ensure they are safe and effective for public use. Investors watch its actions like a referee’s calls: approvals, warnings, inspections or recalls can directly affect a product’s ability to reach the market, a company’s sales and costs, and overall business risk and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

First procedures to be performed in the coming weeks at Alabama's largest non-governmental healthcare system

Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense® in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines

CAESAREA, Israel, Feb. 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced Thomas Hospital of Fairhope, Alabama, part of the Infirmary Health network of hospitals, purchased and installed the ProSense® system, becoming the first facility in Alabama to offer breast cancer cryoablation. Dr. Katelin Holmes, a board-certified breast surgeon, Medical Director of Breast Surgical Services at Thomas Hospital, and Co-Director of the National Accreditation Program for Breast Centers ("NAPBC") Breast Program, will be selecting patients for the procedures, some of which are scheduled to commence their treatment this month.

"Thomas Hospital and Infirmary Health are leading the advancement of breast care in Alabama, where they serve a large population of women from around the Gulf Coast region. We are very pleased that with ProSense®, they will provide the very first breast cancer cryoablation procedures in Alabama over the coming weeks," stated IceCure's Vice President of Sales, North America, Shad Good. "We believe the installation comes on the heels of increased interest in ProSense® following the October 2025 Food and Drug Administration ("FDA") clearance for the local treatment of low-risk breast cancer, and we have observed a growing awareness that may lead to more installations over the coming months."

The hospital's purchase was made possible by the Thomas Hospital Foundation, a nonprofit organization dedicated to supporting Thomas Hospital to access state-of-the-art medical technology to offer innovative and compassionate care for their patients.

Mr. Good continued, "We are highly encouraged that the system was purchased by the Thomas Hospital Foundation as part of its mission to be a leader in delivering the most innovative treatments to patients in their community. Based on the hospital network's patient volume and population, it is our hope that a large number of eligible women will benefit from ProSense® as a minimally invasive treatment option."

Nathan Payne, J.D., M.Ed., Director of the Thomas Hospital Foundation, added, "This technology represents a meaningful step forward for breast care on the Eastern Shore, bringing advanced, less invasive treatment options to patients at Thomas Hospital. The Foundation's role is to thoughtfully steward donor generosity, so we are prepared to invest in innovative, cutting-edge care when opportunities like this arise. It's exciting to see how local philanthropy continues to move healthcare forward at Thomas."

See Thomas Hospital's Instagram post about ProSense® cryoablation for low-risk breast cancer HERE.

About ProSense®

The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.

ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the expectation that breast cancer cryoablation procedures using the ProSense® system will commence at Thomas Hospital over the coming weeks; the belief that interest in ProSense® has increased following the October 2025 FDA clearance for the local treatment of low-risk breast cancer; the observation that growing awareness may lead to additional installations of the ProSense® system over the coming months; ; and the Company's expectations that a large number of eligible women may benefit from ProSense® as a minimally invasive treatment. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/icecure-announces-thomas-hospital-of-infirmary-health-installs-prosense-becomes-first-hospital-in-alabama-to-offer-breast-cancer-cryoablation-302692519.html

SOURCE IceCure Medical

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IceCure (ICCM) announce on February 19, 2026 about ProSense® at Thomas Hospital?

IceCure announced Thomas Hospital installed ProSense® and will offer breast cryoablation in Alabama. According to IceCure, the system was purchased by the Thomas Hospital Foundation and procedures are expected to start in the coming weeks.

When did the FDA clear ProSense® for low-risk breast cancer and why is that important for ICCM?

The FDA cleared ProSense® for local treatment of low-risk breast cancer in October 2025. According to IceCure, that clearance enabled hospital purchases and increased clinical adoption interest across the U.S.

Who will perform the first ProSense® breast cryoablation procedures at Thomas Hospital (ICCM)?

Dr. Katelin Holmes, board-certified breast surgeon and Medical Director of Breast Surgical Services, will select and treat patients. According to IceCure, some procedures are scheduled to commence this month.

How was the ProSense® purchase at Thomas Hospital funded and what does that mean for patients?

The Thomas Hospital Foundation provided purchase funding for the ProSense® system. According to IceCure, foundation support aims to expand access to less invasive breast cancer treatment for local patients.

Is Thomas Hospital part of a larger system and does that affect potential ProSense® patient volume?

Thomas Hospital is part of the Infirmary Health network, a large non-governmental healthcare system. According to IceCure, network patient volume could increase the number of eligible women served.

Will ProSense® procedures start immediately at Thomas Hospital and what is the expected timing?

ProSense® procedures are expected to begin in the coming weeks following installation. According to IceCure, patient selection is underway and some treatments are scheduled this month.